Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAR-200 in NMIBC
NCT02720367Phase 1Completed
- Sponsor
- TARIS Biomedical
- Start
- Jan 2016
- Primary completion
- Jan 2018
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, open-label trial of gemcitabine-releasing intravesical system in non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by TARIS Biomedical. Primary endpoint: Treatment Emergent Adverse Events up to 59 days. Started Jan 2016; status: completed.
02
Drugs
gemcitabine-releasing intravesical system
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT02720367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02720367.